Merck Sharp & Dohme Llc

This study tested a new vaccine called V116 in 313 adults living with HIV to see if it can safely prevent pneumococcal disease (a serious lung infection). Participants received either the new vaccine or an existing one, and researchers monitored side effects and immune responses.…

This study looked at whether giving the HPV vaccine and the Moderna COVID-19 vaccine at the same doctor visit is safe and works as well as giving them separately. It involved 165 boys and girls aged 9 to 11. Researchers measured the immune response and checked for side effects af…

This early-stage study tested a new vaccine formula (V118 Formulation C) in 65 healthy adults to see if it is safe and well-tolerated. Researchers monitored side effects like injection-site reactions and other health events. The study is complete, and results will guide further d…

This early-stage study tested a new vaccine called V330, designed to protect against norovirus—a highly contagious virus that causes vomiting and diarrhea. Researchers gave the vaccine or a placebo to 245 healthy adults split into younger (18-49) and older (60-79) groups. The mai…

This study tested a new vaccine called V116 in 882 children and teenagers (ages 2-17) who are at higher risk for pneumococcal disease due to conditions like diabetes or heart disease. The goal was to see if V116 works as well as or better than the current vaccine PPSV23 in boosti…

This study tested a 9-valent HPV vaccine in nearly 2,000 healthy Chinese females aged 9 to 45. The goal was to see if the vaccine triggers a strong immune response and is safe. Results showed the vaccine works well across all age groups, helping protect against HPV infections tha…

This study tested a new vaccine called V114 to see if it could prevent ear infections caused by certain bacteria in babies. Over 7,000 healthy infants around 2 months old took part. Researchers compared how many babies got vaccine-type ear infections and monitored for serious sid…

This study tested whether adding an experimental drug (MK-4830) to standard chemotherapy and immunotherapy (pembrolizumab) could better reduce tumor DNA in the blood of people with advanced ovarian cancer. 160 participants received treatment before surgery. The goal was to see if…

This study tested an experimental drug called MK-0616 in nearly 3,000 adults with high cholesterol. The goal was to see if it could safely lower 'bad' LDL cholesterol more than a placebo over 24 weeks. Participants either had a history of heart disease or were at high risk, and m…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with triple negative breast cancer. Over 1,100 participants received either pembrolizumab or a placebo with chemo before surgery, then continued the same drug alone after s…

This study tested whether adding lenvatinib to standard chemotherapy plus pembrolizumab helps adults with advanced nonsquamous non-small cell lung cancer live longer or delay cancer growth. Participants were from mainland China and had not received prior treatment for metastatic …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and trastuzumab could help people with advanced HER2-positive stomach or gastroesophageal junction cancer. Over 700 participants received either the combination or a placebo. Results sh…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps women with advanced cervical cancer live longer. Over 600 women with persistent, recurrent, or metastatic cervical cancer took part. The results showed that the combination improv…

This early-phase study tested the safety and how the body processes the drug MK-5684 in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goal was to check for side effects and measure drug levels in the blood. Th…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced solid tumors including breast, ovarian, stomach, colorectal, brain, bile duct, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if…

This early-stage study tested an experimental drug, MK-1454, given as a shot into tumors, either alone or with the immunotherapy pembrolizumab. The goal was to find the safest dose and see if the combination could shrink tumors in people with advanced solid tumors or lymphomas. 1…

This study tested a drug called vericiguat in over 6,000 adults with chronic heart failure and reduced pumping ability. The goal was to see if it could lower the chance of dying from heart problems or being hospitalized for heart failure. Participants took the drug or a placebo a…

This study tested whether adding lenvatinib to the immunotherapy drug pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. Over 600 adults with tumors showing at least 1% PD-L1 took part. The main goals were to see if the c…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This study tested the drug pembrolizumab (Keytruda) given every 6 weeks in 66 adults whose Hodgkin's lymphoma or PMBCL had come back or not responded to prior treatment. The main goal was to see how many participants had their tumors shrink or disappear. Results showed that some …

This study tested two drugs—pembrolizumab and brentuximab vedotin—in 304 people with Hodgkin lymphoma that had returned or not responded to prior treatment. The goal was to see which drug better delayed cancer growth and improved survival. Participants received treatment for up t…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian, fallopian tube, or primary peritoneal cancer that does not have a BRCA mutation. Over 1,300 pa…

This study tested a drug called sotatercept (MK-7962) added to standard treatment for Japanese adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. 46 participants received the drug to see if it improve…

This study tested whether adding lenvatinib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. Over 670 adults who had not received prior treatment for their advanced disease took …

This study tested a new drug combination (MK-4280A) against standard treatments in 94 Chinese adults with advanced colorectal cancer that had spread and no longer responded to prior therapy. The main goal was to see if the new combo helped people live longer. The approach uses tw…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside the…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug or a placebo before and after surgery. The goal was to see if the combination improves outcomes l…

This study tested whether people with HIV whose virus is already well-controlled on a three-drug pill (BIC/FTC/TAF) could safely switch to a new two-drug pill (DOR/ISL) taken once daily. Over 600 participants were followed for 48 weeks. The goal was to see if the simpler pill kep…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. Over 1,200 men participated in this phase 3 trial. The st…

This study tested a new drug called MK-0616 (enlicitide) to see if it lowers 'bad' LDL cholesterol better than current medicines ezetimibe, bempedoic acid, or both combined. About 300 adults with high cholesterol and heart disease risk took part. The main goal was to check choles…

This study tested a drug called ertugliflozin in 166 teenagers (ages 10-17) with type 2 diabetes who were already taking metformin. The goal was to see if adding this drug could lower blood sugar levels more than a placebo. After 24 weeks, the drug helped reduce HbA1C, a key bloo…

This study tested whether adding an experimental drug (MK-1454) directly into tumors, along with the immunotherapy pembrolizumab, works better than pembrolizumab alone for adults with advanced head and neck cancer that has spread or cannot be removed. 18 participants were enrolle…

This early-phase study tested a new drug called boserolimab, given alone or with pembrolizumab, in 182 adults with advanced solid tumors (including lung and breast cancers). The main goals were to check safety and how the drug moves through the body. Participants received treatme…

This study tested a new drug combination (MK-7684A) in 192 adults with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to other treatments. The main goals were to see if the drug is safe and to measure how well it shrinks tumors. The appro…

This study tested whether adding an investigational drug (MK-4830 or MK-0482) to the standard immunotherapy pembrolizumab can help shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 100 adults …

This study tested whether a combination of two drugs (olaparib and pembrolizumab) works better than standard chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. About 462 participants who had already benefited from initial treatm…

This study tested a drug called vorinostat in 56 people with certain types of lymphoma (follicular, other indolent B-cell, or mantle cell) that had returned or stopped responding to prior treatments. The main goal was to see how many patients had their tumors shrink or disappear,…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in people with head and neck cancer that returned or spread and got worse after standard chemotherapy and immunotherapy. The goal was to see if this combo helps people live longer compared to standard che…

This study tested a new medication called MK-0616 in 303 adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). Participants took either the drug or a placebo, and researchers measured how much their bad cholesterol (LDL-C)…

This study tested the drug pembrolizumab (Keytruda) alone or with other medicines in 296 people with high-risk bladder cancer that did not get better after standard BCG therapy. Participants were not able or willing to have their bladder removed. The goal was to see if the treatm…

This early-stage study tested the safety of a new drug called opevesostat (MK-5684) in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy and chemotherapy. The goal was to see if the drug is safe and how it works in the body…

This study tested whether adding one of three experimental drugs to pembrolizumab (an immunotherapy) can help shrink tumors or slow disease in 128 adults with advanced non-small cell lung cancer that had already been treated with a similar immunotherapy. Participants received the…

This study tested the drug lenvatinib in 127 children, adolescents, and young adults whose solid tumors had come back or were not responding to treatment. The goal was to see if the drug could shrink tumors and to check for side effects. Participants were grouped by tumor type, i…

This phase 3 study tested a new combination of two immunotherapy drugs (pembrolizumab and vibostolimab) plus chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. The trial included 739 p…

This study tested a new treatment for people with advanced non-small cell lung cancer that has spread. It compared two drug combinations: one with pembrolizumab and olaparib, and another with pembrolizumab and pemetrexed. The goal was to see which combination helped people live l…

This study tested whether adding two targeted drugs (lenvatinib and pembrolizumab) to standard chemotherapy helps people with advanced stomach or esophageal cancer live longer or slow their cancer growth. About 895 adults with untreated, advanced cancer took part. The goal was to…

This study tested several experimental drug combinations in people with stage III melanoma that could be surgically removed. The goal was to see if adding a new drug to the standard immunotherapy pembrolizumab could improve tumor clearance before surgery. About 146 participants r…

This study compared a combination of two drugs (pembrolizumab and lenvatinib) to standard chemotherapy in 842 women with advanced or recurrent endometrial cancer. The goal was to see if the combo could better delay cancer growth and improve survival. Participants received either …

This study tested whether combining two drugs—pembrolizumab (an immunotherapy) and axitinib (a targeted therapy)—works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 860 participants received either the combination or sunitinib as their…

This study tested whether adding a maintenance drug called olaparib to the standard treatment (pembrolizumab plus chemotherapy) helps people with advanced squamous non-small cell lung cancer live longer or keep the cancer from growing. Over 850 participants received the initial t…

This study tested a new drug combination (MK-4280A) in 441 people with advanced colorectal cancer that had spread and stopped responding to prior treatments. The goal was to see if the new treatment helped people live longer compared to standard therapies. The approach uses two d…

This early-stage study tested the safety of a drug called belzutifan in 29 adults with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to see if different doses were safe and tolerable. Researchers monitored side effects and how the d…

This study tested whether the drug pembrolizumab (an immunotherapy that helps the immune system fight cancer) could prevent liver cancer from returning in people who had already been successfully treated with surgery or ablation. About 959 participants who had no signs of cancer …

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 160 people with a rare type of advanced kidney cancer that had not been treated before. The goal was to see if the drugs could shrink tumors and control the disease. While the treatment may help manage…

This study tested whether the immunotherapy drug pembrolizumab could help prevent non-small cell lung cancer from coming back after surgery. About 1,177 people with stage IB to IIIA lung cancer who had their tumor removed received either pembrolizumab or a placebo. The main goal …

This study tested whether adults with well-controlled HIV could safely switch from a daily pill to a once-weekly combination of two experimental drugs (islatravir and MK-8507). 161 participants who had been virally suppressed for at least 6 months took part. The main goal was to …

This study tested whether adding a fourth drug (lenvatinib) to a standard three-drug regimen (chemotherapy plus immunotherapy) helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 761 adults with a specific type of lung cancer…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 1,579 adults who had not received prior treatment for their advanced cancer took …

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer procedure called TACE helps people with liver cancer that cannot be cured but hasn't spread. About 479 adults took part. The goal was to see if the combination slows cancer growth…

This study tested new drug combinations, with or without the immunotherapy pembrolizumab and chemotherapy, in 90 people with advanced esophageal cancer that had worsened after one prior treatment. The goal was to see if these combinations are safe and help shrink tumors or slow c…

This study tested a new antibiotic called MK-7655A in children from birth to 18 years old who were hospitalized with serious bacterial infections. The goal was to see if the drug is safe and works as well as current treatments. About 115 children took part, and researchers tracke…

This study tested an experimental drug called MK-2060 in 506 people with end-stage kidney disease who need dialysis through a special tube (graft) in their arm. The goal was to see if the drug could prevent dangerous blood clots from blocking the graft. Researchers compared two d…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. It involved 131 Chinese patients who had not received prior treatment for their advanced disease. The goal was t…

This early-phase study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, how the drug moves through the body, and to find …

This study tested experimental drug combinations for people with advanced melanoma that has spread to the brain. It included 56 participants who had not been treated with certain immune therapies or had already received them. The goal was to see if the new combinations were safer…

This early-phase study tested the safety of a new drug called MK-4700, given alone or with another cancer drug (pembrolizumab), in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body handl…

This study tested a new drug combination (MK-4280A) in people with certain skin cancers (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. 163 participants received either the combination or a standard…

This early-phase study tested an experimental drug called MK-4830, either alone or combined with other cancer therapies like pembrolizumab, in 470 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the r…

This study tested whether a combination of two drugs, lenvatinib and pembrolizumab, works better than standard treatments for people with advanced colorectal cancer that has spread to other parts of the body. The trial included 563 adults whose cancer had worsened after or who co…

This early-stage study tested the safety and how the body processes the antibiotic ceftolozane/tazobactam in 41 children with pneumonia caught in the hospital. The main goal was to check for side effects and measure drug levels in the blood. Results help determine the right dose …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct cancer live longer. It involved 158 Chinese adults whose cancer had spread or could not be removed by surgery. The main goal…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. Over 1,000 adults received either the drug combo or chemo alone before and after surgery. The goal was to see if the combi…

This study tested whether adding lenvatinib to pembrolizumab (a standard immunotherapy) helps people with advanced head and neck cancer that has come back or spread. 112 adults with a specific marker (PD-L1) received either the drug combo or pembrolizumab alone. The goal was to s…

This study tested a new drug called MK-1200 in 13 people with advanced stomach, esophageal, bile duct, or pancreatic cancer that had stopped responding to other treatments. The goal was to find the safest dose and see if the drug could shrink tumors. The study was completed and f…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer live longer or delay cancer growth. It included 505 participants who could not take standard platinum chemotherapy. The trial was stopped early because an indepe…

This study tested a new combination of drugs (enfortumab vedotin plus pembrolizumab) given before and after bladder removal surgery for people with muscle-invasive bladder cancer. It compared this approach to the standard chemotherapy (gemcitabine plus cisplatin) given before sur…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination improved the time withou…

This early-phase study tested a drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like leukemia or lymphoma) that had not responded to prior treatments. The main goals were to check safety, side effects, and how the drug moves through the body. Researcher…

This study tested a new medicine called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. The main goal was to see if the drug could stop signs of NASH without making liver scarring worse. Researchers also checked for side effects …

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with Hodgkin lymphoma and other B-cell blood cancers. The goal was to see if the combo is safe and shrinks tumors. Some participants received just one of the drugs for comparison. The study…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …

This study tested whether adding vibostolimab to pembrolizumab (Keytruda) helps people with advanced PD-L1 positive non-small cell lung cancer live longer or keep cancer from growing, compared to pembrolizumab alone. Over 1,200 participants received either the combination or the …

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after surgery to remove the kidney. Nearly 1,000 adults with intermediate-to-high risk of recurrence received either pembrolizumab or a placebo every three we…

This study tested whether adding the immunotherapy drug pembrolizumab to the targeted therapy lenvatinib helps people with advanced liver cancer live longer or delay tumor growth. About 794 adults with advanced liver cancer that could not be treated with surgery or local therapie…

This early-phase study tested a new drug called vibostolimab, either alone or combined with pembrolizumab (and sometimes chemotherapy), in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right…

This study tested whether adding the immunotherapy drug pembrolizumab to standard supportive care helps Asian patients with advanced liver cancer live longer. The trial enrolled 453 patients who had already received one prior treatment. Results showed that pembrolizumab extended …

This study tested a new once-daily combination pill (doravirine/islatravir) in 599 adults newly diagnosed with HIV who had never taken HIV medication. The goal was to see if the new pill could control the virus as well as or better than a standard three-drug regimen. Results show…

This study looked at two ways of giving the drug sotatercept to 164 adults with pulmonary arterial hypertension (PAH), a condition where lung blood vessels narrow, making it hard to breathe. Researchers compared a standard weight-based dose to a simpler weight-banded approach to …

This study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. About 511 adults with a specific type of head and neck cancer took part. The goal was to see if the combination shrinks tumors, delays cancer…

This study looked at whether switching to a new once-daily pill (doravirine/islatravir) is safe and effective for people with HIV whose virus is already suppressed by their current medication. Over 600 adults took part. The main goal was to see if the new pill kept the virus unde…

This study tested whether a combination of two drugs (pembrolizumab and lenvatinib) works better than standard chemotherapy for women with advanced or recurrent endometrial cancer. About 130 women with stage III, IV, or recurrent disease took part. The goal was to see if the comb…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent high-risk skin cancer from returning after surgery and radiation. About 450 adults with advanced squamous cell skin cancer took part. The results suggest that adding pembrolizumab after s…

This study tested a new two-drug combination (MK-4280A) against standard chemotherapy in 203 people with classical Hodgkin lymphoma that had returned or stopped responding to prior treatments, including PD-(L)1 therapy. The goal was to see if the combination could help people liv…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation could help people with advanced head and neck cancer live longer without their disease getting worse. About 800 participants were randomly assigned to receive either pembrolizumab plu…

This study tested a new medicine called clesrovimab in over 1,000 infants and children at high risk for severe RSV disease. The goal was to see if it is safe and works as well as the current standard treatment, palivizumab. Participants received either clesrovimab or palivizumab …

This study tested a new vaccine called V116 in 518 adults aged 18 to 64 who have a higher risk of getting pneumococcal disease (like pneumonia). The goal was to see if V116 is safe and triggers a strong immune response compared to current vaccines. Participants received either V1…

This study tested a new oral medication, MK-8527, taken once a month to see if it is safe and tolerable for preventing HIV. The trial involved 352 HIV-negative adults at low risk of infection. Researchers monitored side effects and how the drug moves through the body, comparing i…

This study tested a new vaccine called V116 to prevent pneumococcal disease (like pneumonia) in adults aged 50 and older. About 1,080 participants received V116 either at the same time as their flu shot or a month apart. Researchers checked if giving both vaccines together was sa…

This study tested a single shot of clesrovimab in over 3,600 healthy preterm and full-term infants to see if it could prevent serious RSV lung infections. The medicine was given before or during RSV season and compared to a placebo. Results showed fewer babies who got the shot ne…

This study tested a new vaccine called V116 in over 1,400 adults aged 50 and older to see if it could prevent pneumococcal disease, which can cause pneumonia and other serious infections. The vaccine was compared to the current standard vaccine (PPSV23). Researchers checked how w…

This study tested whether a higher-than-normal dose of MK-8527, a once-monthly pill to prevent HIV, affects heart rhythm. 42 healthy adults took the study drug, a placebo, or an active control. The main goal was to measure changes in the QT interval, a key heart rhythm marker. Th…

This early-stage study tested the safety and how the body handles a new drug called MK-8189 (elpipodect) in 63 people. It included younger adults with schizophrenia and older adults with or without schizophrenia. The main goal was to check for side effects and see how the drug mo…

This early-stage study tested a new medicine called MK-2828 in 46 adults with type 2 diabetes. The main goal was to see if the drug is safe and well-tolerated. Researchers also measured how the drug moves through the body and whether it affects a marker of inflammation (hsCRP). T…

This early-stage study tested the safety and tolerability of the drug MK-8189 (elpipodect) in 34 adults with stable bipolar I disorder. Participants were in a non-acute phase of their illness and had previously tolerated antipsychotic medication. The study did not test whether th…

This early-stage study tested a new drug called MK-8189 in 53 adults with schizophrenia. The main goal was to see if the drug is safe and tolerable, and to check for any effects on heart rhythm. Participants received multiple doses to monitor side effects and how the drug behaves…

This study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo over 6 weeks. The drug was compared to both a placebo and an active …

This study tested a new drug called MK-8189 (elpipodect) in 224 adults experiencing an acute episode of schizophrenia. Participants received either MK-8189, a placebo, or an active control drug (risperidone) for 4 weeks. The main goal was to see if MK-8189 reduces schizophrenia s…

This early-stage study tested a new medicine called MK-1167 in 28 people with Alzheimer's disease who were already taking donepezil. The main goal was to check if MK-1167 is safe and how the body processes it. Researchers measured side effects and drug levels in the blood to guid…

This early-stage study tested the safety of a drug called MK-8189 in 29 people with Alzheimer's disease, some of whom also had symptoms of agitation or psychosis. The main goal was to see if the drug was safe and tolerable. This is a first step toward finding new treatments for t…

This study looked at how two HIV medicines, doravirine and islatravir, move into breast milk in healthy women who were breastfeeding. Twelve mothers took part, and researchers measured the amount of drug in their milk over 24 hours. The goal was to estimate how much of the drug a…

This study looked at how the drug MK-8527 is processed in people with moderate and severe kidney problems compared to healthy people. 18 adults took a single dose of the drug, and researchers measured drug levels in the blood over time. The goal was to understand how kidney impai…

This study looked at how the drug MK-1084 (calderasib) is absorbed, distributed, and removed from the body in 8 healthy adults. Researchers measured levels in blood, urine, and feces over time. The goal was to understand the drug's metabolism and clearance, not to treat any disea…

This study looked at how the drug calderasib enters the blood when taken as two different tablet types, and whether food changes its absorption. Fifty-two healthy adults participated. The goal was to gather information, not to treat any disease.

This early-stage study tested an experimental drug called MK-8189 (elpipodect) in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to check the drug's safety and how the body absorbs and processes it. Researchers also looked at brain activit…

This study looked at how the experimental prostate cancer drug opevesostat stays in the body over time. Researchers compared 16 men with moderate liver impairment to healthy men. The goal was to see if liver problems affect drug levels, which helps doctors decide on safe dosing.

This study looked at how a new HIV medicine (MK-4646) interacts with a tuberculosis drug (rifabutin) in 18 healthy adults. Researchers measured drug levels in the blood to see if taking both together changes how much MK-4646 is absorbed. The goal is to ensure safe and effective d…

This study looked at how drinking coffee or tea at the same time as a new drug called enlicitide changes the amount of drug in the blood. 60 healthy adults took part, and researchers compared drug levels when taken with coffee, tea, or water. The goal is to see if these common dr…

This early-phase study tested a single injection of a new drug called MK-2060 in 14 people with advanced chronic kidney disease. The main goal was to check safety and how the drug moves through the body. Only the first part was completed; later parts were not started for reasons …

This study looked at how the drug MK-8527, which may be used to prevent HIV, passes into breast milk. Thirteen healthy mothers who were at least 6 weeks postpartum took a single dose. Researchers measured drug levels in their breast milk, blood, and whole blood over 120 hours to …

This study looked at how a drug called belzutifan changes the amount of metformin in the blood and urine of 14 healthy adults. Participants took metformin alone, then metformin with belzutifan, and researchers measured drug levels. The goal was to understand the interaction, not …

This early-stage trial tested the safety and tolerability of a new drug called MK-1167 in 30 healthy adults. Researchers monitored for side effects and whether participants could complete the treatment. The study did not aim to treat any disease, but to gather important safety in…

This study looked at how the drug elpipodect is absorbed, broken down, and removed from the body in 6 healthy adults. Participants gave blood, urine, and stool samples over time to measure the drug and its byproducts. The goal was purely to understand the drug's behavior, not to …

This study looked at how the body processes a drug called MK-1084 when taken alone or with two other common drugs (itraconazole and phenytoin) in 28 healthy adults. The goal was to measure drug levels in the blood to understand potential interactions. This is a Phase 1 trial, mea…

This study looked at how a damaged liver affects the way the body handles a drug called MK-8189. Researchers compared 14 people with moderate liver problems to healthy volunteers after a single dose. The goal was to see differences in drug levels and safety, helping doctors decid…

This study looked at how the drug MK-5684 is processed in the bodies of men with severe kidney disease or end-stage kidney disease compared to healthy men. Researchers measured drug levels in the blood over time and checked for side effects. The goal was to understand how kidney …

This study looked at how the drug MK-4482 is processed by the body and its safety in 16 healthy Chinese men. Participants took single and multiple doses of the drug. The goal was to measure drug levels in the blood and check for side effects. This is an early-stage study with no …

This study looked at how a drug called sotatercept moves through the body when given as a liquid in an autoinjector pen versus a powder form that needs to be mixed. It involved 146 healthy women who are not able to become pregnant. The goal was to see if the two forms work the sa…

This study looked at how the drug ulonivirine moves through the body in 8 healthy adults. Researchers measured how much of the drug was absorbed, broken down, and eliminated in urine and stool. The goal was to understand the drug's path, not to treat any disease.

This completed early-stage study involved 8 healthy men to learn how the investigational drug MK-5475 is absorbed, broken down, and removed from the body. Participants received a single intravenous dose containing a radioactive tracer to track the drug's path. The study did not a…

This study tested whether an experimental HIV medicine called ulonivirine (MK-8507) affects heart rhythm. 62 healthy adults received the drug or a placebo, and researchers measured changes in their heart's electrical activity. The goal was to ensure the drug is safe for the heart…

This study looked at how a new cancer drug called MK-1084 changes the way the body processes two other drugs, midazolam and digoxin. 28 healthy adults took part to help researchers understand if MK-1084 affects the levels of these medicines. The goal was to gather safety and dosi…

This study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy people. 18 adults took a single dose, and researchers measured drug levels over time. The goal was to understand if liver problems change how the …

This study looked at how taking MK-1084 with food, in different pill forms, or with a common heartburn drug changes its levels in the body. 56 healthy adults each took a single dose of MK-1084 under different conditions. The results will help guide how MK-1084 should be taken in …

This study looked at how a single dose of an experimental drug, MK-1084, changes the way the body processes two common medications: rosuvastatin (for cholesterol) and metformin (for diabetes). Sixteen healthy adults took part in a crossover design where each person received the m…

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) causes heart rhythm changes in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug's effect…

This study looked at how the drug bomedemstat (MK-3543) moves through the body in people with mild or moderate liver problems compared to healthy volunteers. Nine participants received a single dose, and researchers measured drug levels in the blood. The goal was to understand if…

This study looked at how the body processes efinopegdutide, a potential drug for fatty liver disease, in people with moderate to severe liver damage compared to healthy people. A total of 22 adults received a single dose, and researchers measured drug levels and safety. The goal …

This study looked at how the drug MK-1084 (calderasib) moves through the body in people with moderate or severe kidney problems compared to healthy people. Researchers measured drug levels in the blood over time and checked for side effects. The goal was to understand if kidney f…